![Michael Cloonan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Cloonan
Directeur Général chez
SIONNA THERAPEUTICS, INC.
Fortune : 24 M $ au 30/06/2026
Profil
Michael Cloonan est directeur de l'exploitation de SAGE Therapeutics, Inc. Dans le passé, il a occupé le poste de Senior Vice President-US Commercial chez Biogen, Inc. M. Cloonan a obtenu un MBA à la Darden School of Business de l'Université de Virginie et un diplôme de premier cycle au College of the Holy Cross (Massachusetts).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/04/2026 | 547 343 ( 1,21 % ) | 24 M $ | 30/06/2026 |
Postes actifs de Michael Cloonan
| Sociétés | Poste | Début |
|---|---|---|
| SIONNA THERAPEUTICS, INC. | Directeur Général | 01/05/2021 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Consultant / Advisor | - |
Anciens postes connus de Michael Cloonan
| Sociétés | Poste | Fin |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/06/2025 |
| SAGE THERAPEUTICS, INC. | Directeur des opérations | 03/05/2021 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2017 |
Formation de Michael Cloonan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
83
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
SAGE Therapeutics, Inc.
 SAGE Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines for central nervous system disorders | Health Technology |
University of Virginia Darden School of Business
 University of Virginia Darden School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
Choisissez Zonebourse 
